(TNS) — There is a surge of interest in career and technical education programs at the secondary school level, fueled by concerns about the cost of college and opportunities to make good money in jobs ...

There is a surge of interest in career and technical education programs at the secondary school level, fueled by concerns about the cost of college and opportunities to make good money in jobs that ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Technology is playing a much bigger role in school districts’ career and technical education programs, a shift that experts say started during the pandemic and is continuing as the use of artificial ...

With the official release of Microsoft's latest database offering, let's see what was improved and what still needs some work. Today, at Ignite, Microsoft announced the general availability of SQL ...

New research shows that CTE may stem from DNA damage and inflammation set in motion by blows to the head. When you purchase through links on our site, we may earn an affiliate commission. Here’s how ...

The NFL season has been rife with tragedy—not that the league or its media partners have noticed. Cleveland Browns player Carl Nassib enters the bue tent during an NFL football game against the New ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...